The Hepatitis B Foundation and the Hep B United coalition are excited to partner with the All of Us Research Program, a program funded by the National Institutes of Health (NIH) to advance precision medicine – health care that is tailored to each person. All of Us will enroll and engage 1 million or more people across the country, from all walks of life, to contribute to research that could improve health for generations to come.
We are partnering with All of Us to increase representation of Asian American and Pacific Islander communities in biomedical research. Diversity and inclusion in health research is critical to understanding how certain diseases or treatments affect individuals differently and helping transform health care to be more customized and effective for each person.
In the U.S., over half of the 2.2 million people living with chronic hepatitis B are Asian Americans and Pacific Islanders. Join All of Us to help researchers better understand the causes and risk factors for chronic conditions like hepatitis B and make health equity a reality.
Visit JoinAllofUs.org to learn more about the All of Us Research Program.
Fact Sheet: All of Us Research Program
Infographic: All of Us Research Program
Flyer: “How do I sign up for the All of Us Research Program?”
WASHINGTON, D.C. (October 24, 2018) – Hep B United today released the following statement, commending Congress for working together to pass the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. The legislation was signed into law by the president, following overwhelming bipartisan Congressional support. The legislation supports a range of services, programs, and funding, across multiple federal agencies, to help combat the nation’s ongoing opioid epidemic and related infectious diseases, including hepatitis B.
The SUPPORT for Patients and Communities Act brings together several pieces of legislation focused on different aspects of the opioid epidemic, from promoting evidence-based prevention strategies, to researching new, non-addictive pain management drugs, and expanding access to substance use disorder treatment.
Continue reading Hep B United Applauds Bipartisan Legislation to Combat the Opioid Crisis and Opioid Related Infectious Diseases →
WASHINGTON, DC (October 18, 2018) Hep B United strongly endorses the introduction of the Liver Illness Visibility, Education and Research (LIVER) Act of 2018. Introduced by Representative Nydia Velazquez (D-NY), the bill takes bold steps to increase investments in research, prevention, and awareness activities to address hepatitis B, which kills up to 1 million people a year, and liver cancer, which continues to grow in incidence and is the 2nd deadliest cancer worldwide. As hepatitis B is the major cause of liver cancer, research efforts to cure these two diseases are linked.
The LIVER Act will authorize $100 million a year for five years for prevention and awareness grants at the Centers for Disease Control and Prevention (CDC) and authorize $45 million a year for five years for hepatitis B and liver cancer research at the National Institutes of Health (NIH). The bill includes significant provisions that will support and accelerate liver cancer and hepatitis B research, and will:
Continue reading Hep B United Endorses the Liver Illness Visibility, Education, and Research (LIVER) Act of 2018 →
WASHINGTON, D.C. (July 2018) – Hep B United, a national coalition established by the Hepatitis B Foundation (HBF) and the Association of Asian Pacific Community Health Organizations (AAPCHO) to address the silent epidemic of hepatitis B, will host its sixth annual summit in Washington, D.C., July 24 to 26. The summit brings together community leaders, advocates and people with hepatitis B to promote screening and prevention strategies and advocate for equitable access to health care to further its mission to eliminate hepatitis B in the United States.
Hepatitis B is caused by a virus and is the world’s most common, serious liver infection. It is also the deadliest vaccine-preventable disease, with nearly 1 million people dying each year from hepatitis B-related disease worldwide. In the United States, up to 2.2 million Americans are chronically infected with hepatitis B, yet most do not know it. Without early diagnosis and intervention, one in four people living with hepatitis B will die prematurely from liver failure or liver cancer.
Continue reading Hepatitis B Leaders Call for the Elimination of Hepatitis B →